The new era of hypertension management: Integrating precision medicine, digital health, and novel therapies
Eurasian Journal of Medicine and Oncology · 19.03.2026 · 026090103
DOI: 10.36922/ejmo026090103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 19.03.2026. Verfasst von Yiling Shi und 4 weiteren Autor:innen.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
Hypertension remains a leading global cause of cardiovascular morbidity and mortality, with a significant proportion of patients failing to achieve adequate blood pressure control despite established therapies. This underscores the urgent need for a paradigm shift toward more integrative and personalized management strategies. Our analysis, based on a narrative review of the current literature, reveals a transformed therapeutic landscape structured across four key pillars. Pharmacologically, novel agents including non-steroidal mineralocorticoid receptor antagonists (finerenone), aldosterone synthase inhibitors (baxdrostat, lorundrostat), and the siRNA therapy zilebesiran offer new mechanisms for resistant hypertension, while optimized low-dose single-pill and quadpill combinations significantly improve adherence. Device-based interventions, particularly renal denervation and baroreflex activation therapy, provide durable blood pressure reduction by modulating neurogenic pathways, supported by robust trial data, though their procedural risks require careful consideration. Precision medicine is advanced through the integration of circulating, genetic, and epigenetic biomarkers, enabling tailored therapy based on individual pathophysiological phenotypes. Digital health technologies, including wearable blood pressure monitors, telemedicine, and AI-driven predictive analytics, facilitate real-time monitoring, improve adherence, and enable proactive management. The future of hypertension care lies in an integrative, patient-centered model that synergistically combines pharmacological innovation, interventional procedures, biomarker-guided precision diagnostics, and digital health tools. Despite promising advances, challenges remain in cost-effectiveness, procedural safety, data integration, and equitable access. Addressing these barriers through coordinated efforts will be essential to translate this modern paradigm into sustainable clinical practice, ultimately optimizing blood pressure control and improving long-term cardiovascular outcomes.
Zitieren
APA
Shi, Y., Li, S., Hang, S., Du, C., & Dai, H. (2026). The new era of hypertension management: Integrating precision medicine, digital health, and novel therapies. Eurasian Journal of Medicine and Oncology, 0(0), 026090103. https://doi.org/10.36922/ejmo026090103
Vancouver
Shi Y, Li S, Hang S, Du C, Dai H. The new era of hypertension management: Integrating precision medicine, digital health, and novel therapies. Eurasian Journal of Medicine and Oncology. 2026;0(0):026090103. doi:10.36922/ejmo026090103
BibTeX
@article{Shi2026,
author = {Shi, Yiling and Li, Sisi and Hang, Suning and Du, Chongchen and Dai, Honglei},
title = {The new era of hypertension management: Integrating precision medicine, digital health, and novel therapies},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {0},
number = {0},
pages = {026090103},
doi = {10.36922/ejmo026090103}
}
EUVIMED